AIF1 and colitis: Although Iba-1 immunoreactivity was increased in both T10–L1 and L6–S1 spinal cord sections of colitis mice (Figure 11E, 11F), administration of MRS2395 at days 2 and 5 of DSS reduced Iba-1 expressing microglia in both segments of the spinal cord (Figure 11E, 11F).